Evidence map›Paper›PMID 37138460›Full record

ArticleHuman vaccines & immunotherapeutics2023

The collective voice of early phase COVID-19 vaccine trial participants: Insights for improving confidence in novel vaccines.

Tonia M Thomas, Susanne H Hodgson, Katherine Emary, Maia Patrick-Smith, Rebecca Te Water Naude, Arabella S V Stuart, John Henry, Marcus English, Maria Moore, Naomi Douglas and 2 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tonia M ThomasOxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.ORCID 0000-0003-3091-5917
Susanne H HodgsonJenner Institute, University of Oxford - Old Road Campus, Oxford, UK.
Katherine EmaryOxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.
Maia Patrick-SmithMedical School, University of Oxford - Old Road Campus, Oxford, UK.
Rebecca Te Water NaudeMedical School, University of Oxford - Old Road Campus, Oxford, UK.
Arabella S V StuartOxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.
John HenryMedical School, University of Oxford - Old Road Campus, Oxford, UK.
Marcus EnglishMedical School, University of Oxford - Old Road Campus, Oxford, UK.
Maria MooreOxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.
Naomi DouglasOxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.
Andrew J PollardOxford Vaccine Group, University of Oxford - Old Road Campus, Oxford, UK.
Samantha VanderslottDepartment of Paediatrics, University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In early 2020, adult volunteers were invited to participate in a first-in-human trial of the COVID-19 vaccine, ChAdOx1 nCoV-19, in the United Kingdom (UK) at the height of the global pandemic when there was uncertainty regarding vaccine efficacy and side-effects. We conducted a retrospective survey of these uniquely situated individuals to gain insight into their views about the risks, motivations, and expectations of the trial and potential vaccine deployment. Our data from 349 respondents show that these volunteers were educated to a high-level with a clear understanding of the seriousness of the COVID-19 pandemic, as well as an appreciation of the role of science and research in developing a vaccine to address this global problem. Individuals were primarily motivated with altruistic intent and expressed a desire to contribute to the scientific effort. Respondents appreciated that their participation was associated with risk but appeared comfortable that this risk was low. Through our analysis, we highlight these individuals as a group with strong levels of trust in science and a sense of societal responsibility, and therefore are a potential valuable resource to improve confidence in novel vaccines. Vaccine trial participants could offer a credible collective voice to support positive messaging around vaccination.

Indexed as

COVID-19VaccinesAdultChAdOx1 nCoV-19COVID-19 VaccinesHumansPandemicsRetrospective StudiesVaccinationChAdOx1 nCoV-19COVID-19 VaccinesVaccinesconfidenceCOVID-19participantsVaccine trial

Identifiers

PMID37138460
PMCPMC10161940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.